U.S., Dec. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07280585) titled 'STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease' on Sept. 24.
Brief Summary: Autosomal dominant polycystic kidney disease is the most common genetic cause of kidney failure. The only approved treatment for ADPKD - tolvaptan - is limited in its use by massive therapy-associated polyuria. This trial tests if the SGLT2-inhibitor dapagliflozin slows down the loss of kidney function in ADPKD.
Study Start Date: Dec. 11
Study Type: INTERVENTIONAL
Condition:
Polycystic Kidney, Autosomal Dominant
Intervention:
DRUG: Dapagliflozin 10 mg
Participants receive 10 mg of Dapagliflozin orally once daily for 36 mo...